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Abstract: L-carnitine supplementation elevates plasma trimethylamine-N-oxide (TMAO), which may
participate in atherosclerosis development by affecting cholesterol metabolism. The aim of the current
study was to determine the effect of increased plasma TMAO on biochemical markers in the blood
following cessation of L-carnitine supplementation. The follow-up measurements were performed
on subjects who completed 24 weeks of L-carnitine or placebo supplementation protocol. Blood
samples were taken after finishing the supplementation and then 4 and 12 months following the
supplementation withdrawal. Four months after cessation of L-carnitine supplementation, plasma
TMAO concentration reached a normal level which was stable for the following eight months. During
this period, no modifications in serum lipid profile and circulating leukocyte count were noted.
TMAO implications in health and disease is widely discussed. The results of this study demonstrate
no adverse effects of elevated plasma TMAO, induced by L-carnitine, on the measured parameters at
4 and 12 months after withdrawal of supplementation.
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1. Introduction
Atherosclerosis is a leading cause of vascular disease worldwide, even if several major modifiable
risk factors have been identified [1]. The early atherosclerotic lesion is characterized by the
accumulation of arterial foam cells derived mainly from cholesterol-loaded macrophages [2]. Thus,
cholesterol metabolism has generated considerable notoriety for its causative role in atherosclerosis [3].
Recent studies suggest that trimethylamine N-oxide (TMAO) may participate in the development of
atherosclerosis [4]. By reducing reverse cholesterol transport, TMAO elevates cholesterol uptake in the
vascular wall, leading to macrophage foam cell formation and atherosclerotic lesion development [4,5].
TMAO may be produced by the intestinal microbiota using L-carnitine as a substrate [5]. Therefore,
L-carnitine has been suggested as a potential link between red meat consumption and atherosclerosis
development [5]. L-carnitine is consumed not only from red meat but as a supplement due to its
potential “fat burning” properties [6]. In fact, dietary L-carnitine supplementation induces TMAO
elevation in human blood [7–10].
The aim of the current study was to determine the effect of increased plasma TMAO on biochemical
markers in the blood following cessation of L-carnitine supplementation.
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2. Materials and Methods
2.1. Subjects
The follow-up measurements were performed on subjects who had completed a study evaluating
the effect of L-carnitine supplementation on skeletal muscle function [11]. Due to personal reasons,
follow-up measurements were discontinued by two subjects. Therefore, the results of 18 women in the
age range of 65–70 years, L-carnitine (n = 10) and placebo (n = 8), were used for statistical analyses.
2.2. Study Procedure
Subjects visited the laboratory after 24 weeks supplementation of either 1500 mg L-carnitine-L-tartrate
or isonitrogenous placebo per day, as described previously [11], and 4 and 12 months following the
cessation of supplementation (Figure 1). The study protocol was approved by the Independent
Bioethics Commission for Research at Medical University of Gdansk (NKBBN/354-304/2015 and
NKBBN/354-201/2017). All subjects gave written informed consent for participation in the study.
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2.3. Fish Consumption Habits
Nutritional intake patterns, especially fish and seafood, have a great impact on TMAO production
in the human body [12]. Therefore, to assess the frequency of fish consumption, a specific survey
was constructed in a comprehensible form that was easily filled out by all subjects. The survey used
quantitative research methods to identify “frequency consumption groups” [13]:
F0—never/occasionally,
F1—1–2 times per month,
F2—once per week,
F3—2–5 times per week,
F4—every day.
2.4. Blood Sampling
Fasting blood samples were taken from the antecubital vein. White blood cell (WBC) count and
differential leukocyte count were determined using an automated hematology analyzer (Sysmex XT
2000, Global Medical Instrumentation, Inc (Mundelein, IL, USA)) in the whole blood. Serum and
EDTA-plasma were obtained by centrifugation at 2000× g at 4 ◦C for 10 min. Samples were stored at
−80 ◦C until analyses.
2.5. Biochemical Determination
Plasma TMAO was determined by the UPLC/MS/MS method as described previously [14]. Total
cholesterol (TCh), high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol,
and triglycerides (TG) were determined using Cobas6000 (Roche Diagnostics, Mannheim, Germany).
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2.6. Statistical Analyses
Statistical calculations were performed using Statistica 13.1 (Dell Inc., Tulsa, OK, USA). The
analysis of variance (ANOVA) for repeated measurements was performed to examine the interaction
between the treatment and time, with Tukey–Kramer post hoc comparisons. A probability level of
p < 0.05 was considered statistically significant. All data are expressed as mean ± standard error (SE).
3. Results
At the end of the supplementation protocol, the plasma TMAO concentration reached 33.6± 6.7µM
in the L-carnitine group, whereas it was 2.9 ± 0.3 µM in the placebo group (Figure 1). Four months
after cessation of supplementation, plasma TMAO decreased to a level comparable to the placebo
group and remained stable for the following eight months (Figure 2).
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Figure 2. Plasma trimethylamine-N-oxide (TMAO) concentrations in placebo and L-carnitine groups.
* p < 0.001 as compared to placebo group at the same time point, ‡ p < 0.001 as compared to the end of
supplementation in the same group.
During the same time intervals, circulating lipid profile metabolites were not modified by either
the supplementation or the washout period (Table 1).
Table 1. Serum lipid metabolites in L-carnitine and placebo groups after 24 weeks of supplementation
(end) and 4 and 12 months after cessation of supplementation.
L-carnitine Placebo
End 4 Months 12 Months End 4 Months 12 Months
TCh (mg·dL−1) 217 ± 12 213 ± 16 211 ± 13 199 ± 15 211 ± 10 202 ± 11
HDL (mg·dL−1) 67 ± 5 72 ± 6 70 ± 5 61 ± 4 72 ± 7 67 ± 5
LDL (mg·dL−1) 127 ± 10 119 ± 14 115 ± 12 117 ± 13 120 ± 10 117 ± 7
TG (mg·dL−1) 114 ± 18 116 ± 14 130 ± 22 103 ± 18 98 ± 12 89 ± 14
TCh: total cholesterol; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol;
TG: triglycerides.
Similarly, the leukocyte count remained unchanged and was not different between the groups
(Table 2).
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Table 2. Circulating white blood cell counts in L-carnitine and placebo groups after 24 weeks of
supplementation (end) and 4 and 12 months after cessation of supplementation.
L-carnitine Placebo
End 4 Months 12 Months End 4 Months 12 Months
Leuko (109·L−1) 5.7 ± 0.5 6.1 ± 0.6 6.6 ± 0.8 5.4 ± 0.4 5.7 ± 0.5 5.5 ± 0.4
Neutro (109·L−1) 3.0 ± 0.3 3.4 ± 0.5 3.7 ± 0.5 3.0 ± 0.2 3.0 ± 0.4 2.7 ± 0.2
Lympho (109·L−1) 2.0 ± 0.2 2.0 ± 0.2 2.1 ± 0.2 1.8 ± 0.2 2.1 ± 0.2 2.1 ± 0.2
NLR 1.6 ± 0.2 1.7 ± 0.2 1.8 ± 0.2 1.7 ± 0.2 1.5 ± 0.2 1.4 ± 0.1
Mono (109·L−1) 0.51 ± 0.04 0.51 ± 0.03 0.54 ± 0.05 0.45 ± 0.06 0.46 ± 0.06 0.45 ± 0.04
Platelets (109·L−1) 279 ± 16 272 ± 12 291 ± 13 249 ± 19 248 ± 18 253 ± 23
Leuko: leukocytes; Neutro: neutrophils; Lympho: lymphocytes; NLR: neutrophil-to-lymphocyte ratio;
Mono: monocytes.
No differences in fish consumption habits were noted (Table 3).
Table 3. The frequency of fish consumption.
L-carnitine Placebo
Median Range Median Range
Cod F1 F0–F3 F1 F0–F3
Salmon F1 F0–F2 F2 F0–F3
Mackerel F1 F0–F2 F1 F0–F2
Herring F1 F0–F3 F1 F0–F3
Trout F0 F0–F1 F1 F0–F3
Tuna F0 F0–F1 F0 F0–F2
Flounder F0 F0–F1 F0 F0–F1
Hake F0 F0–F1 F0 F0–F1
Eel F0 F0–F1 F0 F0–F1
Pollock F0 F0–F1 F0 F0–F1
F0: never/occasionally; F1: 1–2 times per month; F2: once per week; F3: 2–5 times per week.
4. Discussion
The main finding of the current study is that four months after cessation of L-carnitine
supplementation, plasma TMAO concentration reached a normal level which was stable for the
following eight months. During this period, no modifications in serum lipid profile and circulating
leukocyte count were noted.
Elevated plasma TMAO has been suggested as a predictor of poor prognosis in cardiovascular
disease patients associated with increased risk of major adverse cardiovascular events or death [15–18].
However, adjustment for kidney function abolishes the statistical significance of plasma TMAO in
relation to patients’ mortality [18]. It is worth noting that cardiovascular disease and kidney disease
are closely interrelated [19] and diminished renal function is strongly associated with morbidity and
mortality in heart failure patients [20]. Moreover, at the beginning of this century, elevated plasma
TMAO levels were detected in patients with chronic renal disease [21] and were suggested as a marker
of ischemic kidney damage [22]. Glomerular filtration rates of the subjects participating in this study
were within the normal range [10], and four months after cessation of L-carnitine treatment, TMAO
decreased to a level comparable to the values observed before supplementation started [10].
Higher risks of all-cause and cardiovascular disease mortality have been linked to red meat
consumption [23], with TMAO as a potential link between red meat consumption and atherosclerosis
development [5]. However, in the German adult population, meat consumption was not related to
plasma TMAO [24]. Moreover, a minor increase in plasma TMAO was observed following red meat
and processed meat consumption, whereas fish induced significant elevation of plasma TMAO [25].
Furthermore, Veeravalli et al. [26] reported that TMAO does not increase plasma cholesterol or act as a
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proatherogenic molecule under normal dietary conditions. Levels of red meat and fish consumption
of the subjects participating in this study were similar in both groups [11] and did not differ from
nutritional habits in this region [13].
TMAO is produced using L-carnitine as a substrate [5]; thus, L-carnitine supplementation
elevates plasma TMAO [7–10]. In patients with inborn errors of metabolism who require L-carnitine
supplementation, the average plasma TMAO reached 120 µM, which was ~45-fold higher compared
with patients without a diagnosed genetic disorder on a standard omnivorous Western diet that was
not supplemented by L-carnitine [8]. Vallance et al. [9] reported that L-carnitine treatment (1000 mg
daily for >1 year) of patients with mitochondrial disorders induced a ~12-fold increase in median
TMAO concentration (3.54 vs. 43.26 µM). It is worth noting that one subject with chronic kidney
disease had a marked elevation of plasma TMAO at baseline (33.98 µM), which increased 3-fold on
oral L-carnitine therapy (33.98 vs. 101.6 µM) [9]. Healthy aged women, participating in the current
study, were supplemented by 1500 mg L-carnitine-L-tartrate per day for 24 weeks [11]. A 10-fold
increase of plasma TMAO was noted after 12 weeks of supplementation and remained elevated for
the next 12 weeks [10]. Considering the increase of relative risk for all-cause mortality by 7.6% per
each 10 µM increment of TMAO [27], and TMAO elevation due to L-carnitine supplementation [7–10],
the negative impact of L-carnitine should have been observed. However, L-carnitine has been used
as a treatment for cardiovascular disease patients for decades with no detrimental effects reported
(for review, see [28–30]). Even if the positive effect of L-carnitine has been recently negated, as there
is no significant marginal benefit in terms of all-cause mortality, heart failure, unstable angina, or
myocardial reinfarction [28], it has still not been shown to be a harmful compound—although much
higher doses (e.g., 6 g/day for a period of 1 year) have been tested in patients with acute anterior
myocardial infarction [31]. Furthermore, genetic variants of organic cation transporter 2 reduce cardiac
uptake of carnitine, leading to heart failure [32].
The number of subjects examined in our study was very small. Another limitation is the relatively
short period of supplementation. Since atherosclerosis develops over the course of years, 24 weeks
may be not sufficient to induce any changes in the determined metabolites. However, we have
noted that a 10-fold plasma TMAO increase, induced by L-carnitine supplementation, does not affect
inflammatory markers (i.e., vascular cell adhesion molecule, intercellular adhesion molecule, L-selectin,
P-selectin, C-reactive protein, tumor necrosis factor α, and interleukin-6 [10]) and oxidative stress
markers (unpublished). Moreover, the neutrophil-to-lymphocyte ratio (NLR), an index of systemic
inflammation associated with subclinical atherosclerosis [33], during and after the supplementation
remained at a level ≤ 1.8, which was comparable to the control subjects [34]. Nevertheless, it remains
unknown whether other inflammatory markers, not determined in previous studies, are influenced by
carnitine supplementation.
5. Conclusions
TMAO implications in health and disease are widely discussed [35–37], but it is still debated
whether it is a mediator in human disease development or a causative agent in the disease process [38,39].
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